01
Damage signal
Injured cells and tissue generate molecular signals, including S1P.
Barcelona · Advanced regenerative cell science
MUSE Cells.
Repair intelligence within the cell.
A clear patient guide to Multilineage-differentiating Stress Enduring cells: how they recognise signals from damaged tissue, how they differ from conventional mesenchymal stromal cells, and how a specialist Barcelona pathway can be evaluated.
SSEA-3+identified population
S1PR2damage-signal receptor
IV studiedsystemic delivery research
01 · The cell
What exactly is a MUSE cell?
MUSE is not a marketing synonym for every stem cell. It refers to a naturally occurring, stress-enduring population identified within mesenchymal tissues and cell preparations. Published research commonly characterises MUSE cells by SSEA-3 positivity together with mesenchymal markers.
Multilineage-differentiating Stress Enduring
MUSE cells were described as a small population within broader mesenchymal stromal cell preparations. In laboratory studies they express pluripotency-associated markers at moderate levels and can generate cell types representing the three embryonic germ layers. Unlike embryonic stem cells and induced pluripotent stem cells, MUSE cells have not shown teratoma formation in the foundational experimental literature.
The word stress-enduring reflects their ability to survive conditions that eliminate many other cells. This resilience is relevant because injured tissue is inflammatory, oxygen-poor and biologically hostile.
MMultilineage
U—
SStress
EEnduring
02 · Proposed repair sequence
How MUSE cells find damaged tissue
The best-described homing mechanism involves sphingosine-1-phosphate (S1P), a signal released in increased amounts by damaged cells, and its receptor S1PR2 on MUSE cells. The sequence below is a simplified educational model based on experimental research.
02
Recognition
S1PR2 expressed by MUSE cells participates in sensing the S1P gradient.
03
Homing
In animal studies, intravenously delivered MUSE cells preferentially migrate towards injured tissue.
04
Participation in repair
After arrival, experimental studies report survival, tissue-compatible differentiation and paracrine support.
For patients: “Homing” does not mean that every injected cell reaches an organ, and “differentiation” does not guarantee restoration of organ function. These are measurable biological mechanisms whose clinical impact must be demonstrated separately for each disease and product.
03 · Scientific comparison
MUSE cells versus conventional MSC preparations
Both populations may provide anti-inflammatory, antifibrotic and tissue-supporting signals. The central experimental distinction is that selected MUSE cells show stronger targeted homing and direct tissue integration in several models, while ordinary MSC effects are often predominantly paracrine.
Conventional MSC preparation
- Heterogeneous mesenchymal stromal cell population.
- MUSE cells may represent only a small fraction of the preparation.
- Many reported effects are associated with secreted factors and immune modulation.
- After intravenous administration, pulmonary retention is common.
- Evidence for one MSC product cannot automatically validate another.
MUSE cell preparation
- Selected and characterised MUSE population rather than generic MSC branding.
- Stress endurance and moderate pluripotency-associated marker expression.
- S1P–S1PR2-associated homing towards damaged tissue.
- Direct integration and tissue-compatible differentiation reported in animal models.
- Early clinical programmes have studied intravenous allogeneic products.
Experimental homing comparison
Illustrative comparison reported in a rabbit acute myocardial infarction model after intravenous administration—not a universal human treatment rate. Yamada and colleagues’ model, summarised in Dezawa 2025, found approximately 15% homing for MUSE cells and fewer than 1% for non-MUSE MSCs.
04 · Evidence map
Where the science stands today
MUSE cell research has progressed from cell biology and animal models into early human studies. The evidence is promising but indication-specific. “Studied in people” is not the same as universally approved or proven.
RANDOMISED EXPLORATORY TRIAL
Subacute ischaemic stroke
A small placebo-controlled study evaluated a single intravenous dose of allogeneic CL2020 14–28 days after stroke. It provided an important clinical signal while remaining exploratory because of sample size and the need for confirmation.
Read the publication →FIRST-IN-HUMAN
Acute myocardial infarction
An early clinical report assessed intravenous CL2020 after STEMI and described feasibility, safety observations and cardiac-function signals. Larger controlled studies are required to establish benefit.
Read the publication →SAFETY & FEASIBILITY
Traumatic spinal cord injury
A human study evaluated a single intravenous donor-MUSE-cell administration in cervical traumatic spinal cord injury, focusing first on safety and feasibility.
Read the publication →PRECLINICAL
Liver and fibrosis models
Experimental studies report homing, differentiation towards liver-associated cell types and antifibrotic or protective effects. This does not yet establish routine clinical treatment of human cirrhosis.
Review the evidence →PRECLINICAL
Neurological injury
Animal models of stroke, spinal injury and other neurological damage show migration to lesions and neural-lineage participation. Human efficacy must be established independently.
View spinal-injury research →PLATFORM BIOLOGY
Why selection matters
A genuine MUSE-cell claim should identify the selected population, characterisation method, purity, viability, dose, manufacturer and certificate of analysis. Generic MSCs should not be relabelled as MUSE cells.
Foundational comparison →05 · Visual cell atlas
One regenerative system, many tissue contexts
These images are educational visualisations rather than patient histology. They illustrate the different cellular environments investigated in regenerative science.
Neural context
Research asks whether targeted cells can survive, support neural networks and participate in tissue repair after injury.
Cardiac context
Models assess homing to ischaemic myocardium, integration, scar size and functional recovery.
Hepatic context
Liver studies examine cellular replacement, inflammation, fibrosis and functional markers.
07 · Patient questions
What should I ask before proceeding?
A serious programme welcomes verification. These questions help separate documented MUSE-cell science from a generic stem-cell offer.
Is the preparation genuinely MUSE-cell selected?
Ask for SSEA-3-based characterisation, the percentage of the selected population and a certificate of analysis. The mere presence of a small number of MUSE cells inside an ordinary MSC preparation does not make the product equivalent to a selected MUSE-cell preparation.
What evidence applies to my diagnosis?
Request the publication for the same condition, cell product, route and disease stage. Evidence from an animal liver model cannot prove benefit after human stroke, and an exploratory stroke trial cannot validate every neurological indication.
Will the cells rebuild my organ?
Experimental studies support homing, integration and tissue-compatible differentiation. Human organ repair is a clinical outcome that must be demonstrated for each indication. No responsible clinician should guarantee organ reconstruction or functional recovery.
Is treatment definitely available in Barcelona?
Barcelona can provide the setting for case assessment and coordinated clinical and laboratory planning. Actual administration depends on product access, physician approval, facility documentation and the applicable regulatory route at the time of treatment.
What follow-up is required?
A written plan should define clinical outcomes, laboratory monitoring, imaging where appropriate, adverse-event reporting, rehabilitation and communication with the patient’s home physician.
08 · Source library
Selected scientific sources
Patients and clinicians should open the original publications and verify that each claim matches the studied product, population and endpoint.
- Muse Cells Provide the Pluripotency of Mesenchymal Stem Cells.
- MUSE cells and the S1P–S1PR2 homing mechanism.
- Multilineage-differentiating stress-enduring cells: 2024 review.
- Randomised placebo-controlled CL2020 stroke trial.
- First-in-human CL2020 myocardial infarction report.
- MUSE cells in human traumatic spinal cord injury: safety and feasibility.
- Intravenous human MUSE cells in experimental spinal cord injury.
- Comparison of MSCs and MUSE cells.
Private international contact
Begin with evidence. Continue with an individual review.
Send the diagnosis, age, current treatment and recent medical reports. NBScience will assess whether a documented MUSE-cell discussion is scientifically and operationally appropriate.